[go: up one dir, main page]

BRPI0819211A2 - Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo - Google Patents

Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo

Info

Publication number
BRPI0819211A2
BRPI0819211A2 BRPI0819211-1A BRPI0819211A BRPI0819211A2 BR PI0819211 A2 BRPI0819211 A2 BR PI0819211A2 BR PI0819211 A BRPI0819211 A BR PI0819211A BR PI0819211 A2 BRPI0819211 A2 BR PI0819211A2
Authority
BR
Brazil
Prior art keywords
immunoassay
polynucleotide
antibody
kit
producing
Prior art date
Application number
BRPI0819211-1A
Other languages
English (en)
Inventor
Donmienne Doen Mun Leung
Peng Luan
Barbara Anne Swanson
Ying Tang
Derrick Ryan Witcher
Yuping Anthony Cai
Dennis Patrick Gately
Luhong He
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0819211(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0819211A2 publication Critical patent/BRPI0819211A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0819211-1A 2007-11-02 2008-10-29 Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo BRPI0819211A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98491007P 2007-11-02 2007-11-02
PCT/US2008/081493 WO2009058797A1 (en) 2007-11-02 2008-10-29 Anti-hepcidin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0819211A2 true BRPI0819211A2 (pt) 2015-06-16

Family

ID=40383701

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819211-1A BRPI0819211A2 (pt) 2007-11-02 2008-10-29 Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo

Country Status (34)

Country Link
US (3) US7820163B2 (pt)
EP (2) EP2209806B1 (pt)
JP (1) JP5469076B2 (pt)
KR (2) KR20120107145A (pt)
CN (1) CN103492414B (pt)
AR (1) AR069062A1 (pt)
AU (1) AU2008318850B2 (pt)
BR (1) BRPI0819211A2 (pt)
CA (1) CA2704527C (pt)
CL (2) CL2008003190A1 (pt)
CO (1) CO6231037A2 (pt)
CR (1) CR11414A (pt)
CY (1) CY1113630T1 (pt)
DK (1) DK2209806T3 (pt)
DO (2) DOP2010000123A (pt)
EA (1) EA023406B1 (pt)
ES (1) ES2392123T3 (pt)
HR (1) HRP20120870T1 (pt)
IL (1) IL205355A (pt)
JO (1) JO2828B1 (pt)
MA (1) MA31886B1 (pt)
MX (1) MX2010004841A (pt)
MY (1) MY155708A (pt)
NZ (2) NZ598391A (pt)
PE (1) PE20091261A1 (pt)
PL (1) PL2209806T3 (pt)
PT (1) PT2209806E (pt)
RS (1) RS52592B (pt)
SI (1) SI2209806T1 (pt)
TN (1) TN2010000201A1 (pt)
TW (1) TWI409276B (pt)
UA (1) UA98983C2 (pt)
WO (1) WO2009058797A1 (pt)
ZA (1) ZA201003025B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053268A1 (en) * 2006-10-17 2011-03-03 Naohisa Tomosugi Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator
PE20090722A1 (es) 2007-02-02 2009-07-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
JPWO2008146903A1 (ja) * 2007-05-31 2010-08-19 直久 友杉 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法
TWI409276B (zh) 2007-11-02 2013-09-21 Lilly Co Eli 抗－海帕西啶（ｈｅｐｃｉｄｉｎ）抗體及其用途
ES2487846T3 (es) * 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
AU2009279865B2 (en) * 2008-08-06 2013-10-10 Eli Lilly And Company Anti-hepcidin-25 selective antibodies and uses thereof
DE102009034150A1 (de) * 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
JP2013502399A (ja) 2009-08-20 2013-01-24 ヴィフォール （インターナショナル） アクチェンゲゼルシャフト 新規なキノリン系ヘプシジン拮抗薬
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
JP2013503835A (ja) 2009-09-07 2013-02-04 ヴィフォール （インターナショナル） アクチェンゲゼルシャフト 新規なエタンジアミン系ヘプシジン拮抗薬
WO2011029832A1 (de) 2009-09-09 2011-03-17 Vifor (International) Ag Neue thiazol- und oxazol-hepcidin-antagonisten
WO2011071368A1 (en) 2009-12-11 2011-06-16 Umc St. Radboud Method for measuring hepcidin
US9051382B2 (en) * 2010-08-16 2015-06-09 Pieris Ag Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins that bind hepcidin and nucleic acid encoding such
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
SG10201604574UA (en) 2011-12-12 2016-07-28 Pieris Ag Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
MX359794B (es) * 2013-03-15 2018-10-10 Intrinsic Lifesciences Llc Anticuerpos anti-hepcidina y usos de los mismos.
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CN104945497B (zh) * 2014-11-21 2018-04-03 南京国龙生物科技有限公司 一种新型抗菌肽Hep‑W及其制备方法和应用
WO2016137950A1 (en) 2015-02-24 2016-09-01 Rpeptide, Llc Anti-tau antibodies
EP3268027B1 (en) 2015-03-13 2022-11-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Hepcidin antagonists for use in the treatment of inflammation
TWI789343B (zh) 2016-02-01 2023-01-11 丹麥商碩騰丹麥有限公司 微流體分析系統、執行分析的微流體匣及方法
WO2018234538A1 (en) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism
EP3461841B1 (en) 2017-10-02 2019-09-11 Certest Biotec, S.L. Anti-dps antibodies and test devices for the detection of bacteria of the genus campylobacter
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
WO2021222875A1 (en) 2020-04-30 2021-11-04 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
JP2023528223A (ja) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6262247B1 (en) 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
AU2002321105A1 (en) 2001-05-25 2002-12-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
CN1173737C (zh) 2002-10-21 2004-11-03 钱忠明 Hepcidin(海魄喜定)在制药中的应用
EP1578254B1 (en) * 2002-11-19 2013-03-06 DRG International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
CA2537668A1 (en) 2003-09-29 2005-04-14 Biosite Incorporated Methods and compositions for the diagnosis of sepsis
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
EP1853630A1 (en) 2004-10-22 2007-11-14 Applied Molecular Evolution Inc. Methods of optimizing antibody variable region binding affinity
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006099126A2 (en) 2005-03-11 2006-09-21 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
PE20090722A1 (es) * 2007-02-02 2009-07-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
CN101903044A (zh) 2007-10-02 2010-12-01 国家健康与医学研究院 对人铁调素具有特异性的抗原结合蛋白
TWI409276B (zh) 2007-11-02 2013-09-21 Lilly Co Eli 抗－海帕西啶（ｈｅｐｃｉｄｉｎ）抗體及其用途
ES2487846T3 (es) 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
AU2009279865B2 (en) * 2008-08-06 2013-10-10 Eli Lilly And Company Anti-hepcidin-25 selective antibodies and uses thereof

Also Published As

Publication number Publication date
KR20120107145A (ko) 2012-09-28
CL2012001710A1 (es) 2013-04-12
AR069062A1 (es) 2009-12-23
NZ598391A (en) 2013-07-26
CY1113630T1 (el) 2016-06-22
DOP2013000205A (es) 2013-12-15
US7820163B2 (en) 2010-10-26
EP2209806A1 (en) 2010-07-28
US20130164304A1 (en) 2013-06-27
CL2008003190A1 (es) 2009-09-04
JP2011502482A (ja) 2011-01-27
US8765129B2 (en) 2014-07-01
AU2008318850B2 (en) 2014-05-29
EA201070553A1 (ru) 2010-10-29
EP2527368B1 (en) 2016-08-24
ZA201003025B (en) 2011-11-30
HK1142341A1 (en) 2010-12-03
NZ584997A (en) 2012-06-29
CR11414A (es) 2010-08-05
CA2704527C (en) 2015-12-15
EA023406B1 (ru) 2016-06-30
RS52592B (sr) 2013-04-30
CA2704527A1 (en) 2009-05-07
JO2828B1 (en) 2014-09-15
PT2209806E (pt) 2012-10-03
IL205355A0 (en) 2010-12-30
WO2009058797A1 (en) 2009-05-07
CN103492414B (zh) 2016-04-13
AU2008318850A1 (en) 2009-05-07
IL205355A (en) 2015-05-31
TW200927759A (en) 2009-07-01
US20090136495A1 (en) 2009-05-28
US20110027261A1 (en) 2011-02-03
PE20091261A1 (es) 2009-08-17
EP2209806B1 (en) 2012-08-22
CO6231037A2 (es) 2010-12-20
JP5469076B2 (ja) 2014-04-09
MX2010004841A (es) 2010-07-30
UA98983C2 (uk) 2012-07-10
HRP20120870T1 (hr) 2012-11-30
DOP2010000123A (es) 2010-08-15
SI2209806T1 (sl) 2012-11-30
DK2209806T3 (da) 2012-09-17
KR101335059B1 (ko) 2013-12-11
ES2392123T3 (es) 2012-12-04
US8329174B2 (en) 2012-12-11
TN2010000201A1 (en) 2011-11-11
KR20100067682A (ko) 2010-06-21
MA31886B1 (fr) 2010-12-01
EP2527368A1 (en) 2012-11-28
CN103492414A (zh) 2014-01-01
MY155708A (en) 2015-11-13
PL2209806T3 (pl) 2013-01-31
TWI409276B (zh) 2013-09-21

Similar Documents

Publication Publication Date Title
BRPI0819211A2 (pt) Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo
BRPI0922106A2 (pt) anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
CL2014000400A1 (es) Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
BRPI0821447A2 (pt) Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
BR112012004221A2 (pt) "anticorpos, composição farmacêutica, uso do anticorpo, ácido nucleico, vetores de expressão, célula hospedeira procariótica e método para a produção de um anticorpo humanizado recombinante"
BRPI0812400A2 (pt) Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
BRPI0717768A2 (pt) Anticorpo, epítipo, seqüência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, e, uso de um anticorpo
BRPI0816094A2 (pt) Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
BRPI0821375B8 (pt) anticorpos biespecíficos, bivalentes, processo para a preparação destes e composição farmacêutica dos mesmos
BRPI0905076A2 (pt) Polipeptídeo, anticorpo, região variável, cadeia pesada ou cadeia leve, gene, vetor, célula hospedeira, método para produzir o referido polipeptídeo, e composição farmacêutica compreendendo o mesmo
BR112012022046A2 (pt) ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
BR112013029893A2 (pt) molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
BRPI0819688A2 (pt) Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
BRPI0919377A2 (pt) anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI0822447A2 (pt) Anticorpo monoclonal e método do mesmo
BRPI0821682A2 (pt) Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.
LT3421498T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
BR112012003809A2 (pt) anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
BRPI0818780A2 (pt) Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
BRPI0813645A2 (pt) Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
CR10705A (es) Anticuerpos para linfotoxina-alfa
BRPI0817182A2 (pt) Método para purificar um anticorpo e composições
BRPI0916964A2 (pt) polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
HUE032894T2 (hu) VEGF-gátló, stabilis és oldható antitestek

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.